Clinica Universidad de Navarra CIMA IDISNA CIBERONC Pamplona Spain

Department of Clinical Therapeutics School of Medicine National and Kapodistrian University of Athens Greece

Department of Hematology Amsterdam UMC Vrije Universiteit Amsterdam Cancer Center Amsterdam The Netherlands

Department of Hematology University Hospital Hôtel Dieu Nantes France

Department of Hematology University Hospital Leuven Belgium

Department of Internal Medicine 2 University Hospital Wurzburg Germany

Department of Oncology and Hematology Kantonsspital Graubünden Chur Switzerland

Division of Hematology University of Torino AOU Città della Salute e della Scienza di Torino Italy

Erasmus Medical Center Cancer Institute Rotterdam The Netherlands

Faculty of Medicine University Hospital Ostrava Czech Republic

Hôpital Claude Huriez Lille University Hospital Lille France

KG Jebsen Center for B Cell Malignancies University of Oslo Norway

Leeds Cancer Centre and University of Leeds United Kingdom

Oslo Myeloma Center Oslo University Hospital Oslo Norway

Seràgnoli Institute of Hematology Bologna University School of Medicine Bologna Italy

University Hospital Heidelberg Internal Medicine 5 and National Center for Tumor Diseases Heidelberg Germany

University Hospital of Salamanca IBSAL Cancer Research Center Salamanca Spain

Erratum In

Hemasphere. 2021 Mar 31;5(4):e567. doi: 10.1097/HS9.0000000000000567. PubMed

Erratum In

Hemasphere. 2021 Nov 29;5(12):e659. doi: 10.1097/HS9.0000000000000659. PubMed

See more in PubMed

Usmani SZ, Hoering A, Cavo M, et al. . Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG research project. Blood Cancer J. 2018; 8:123. PubMed PMC

Moreau P, San Miguel J, Sonneveld P, et al. . Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28suppl_4iv52–iv61 PubMed

Caers J, Garderet L, Kortüm KM, et al. . European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica. 2018; 103:1772–1784 PubMed PMC

Kumar S, Paiva B, Anderson KC, et al. . International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17:e328–e346 PubMed

Alonso R, Cedena MT, Wong S, et al. . Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma. Blood Adv. 2020; 4:2163–2171 PubMed PMC

Perrot A, Lauwers-Cances V, Corre J, et al. . Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018; 132:2456–2464 PubMed PMC

Munshi NC, Avet-Loiseau H, Rawstron AC, et al. . Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017; 3:28–35 PubMed PMC

Cavo M, Terpos E, Nanni C, et al. . Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017; 18:e206–e217 PubMed

Avet-Loiseau H, Ludwig H, Landgren O, et al. . Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: a meta-analysis. Clin Lymphoma Myeloma Leuk. 2020; 20:e30–e37 PubMed PMC

Rajkumar SV, Dimopoulos MA, Palumbo A, et al. . International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15:e538–e548 PubMed

Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood. 2015; 125:3069–3075 PubMed PMC

Mateos MV, Hernández MT, Giraldo P, et al. . Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013; 369:438–447 PubMed

Mateos MV, Hernández MT, Giraldo P, et al. . Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol. 2016; 17:1127–1136 PubMed

Lonial S, Jacobus S, Fonseca R, et al. . Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol. 2020; 38:1126–1137 PubMed PMC

Landgren CO, Chari A, Cohen YC, et al. . Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia. 2020; 34:1840–1852 PubMed PMC

Cavo M, Gay F, Patriarca F, et al. . Double autologous stem cell transplantation significantly prolongs progression-free survival and overall survival in comparison with single autotransplantation in newly diagnosed multiple myeloma: an analysis of phase 3 EMN02/HO95 study. Blood. 2017; 130suppl 1401

Attal M, Lauwers-Cances V, Hulin C, et al. ; IFM 2009 Study. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017; 376:1311–1320 PubMed PMC

Cavo M, Gay F, Beksac M, et al. . Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020; 7:e456–e468 PubMed

Sonneveld P, Goldschmidt H, Rosiñol L, et al. . Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol. 2013; 31:3279–3287 PubMed

Moreau P, Hulin C, Macro M, et al. . VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood. 2016; 127:2569–2574 PubMed

Mai EK, Bertsch U, Dürig J, et al. . Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia. 2015; 29:1721–1729 PubMed

Rosiñol L, Oriol A, Rios R, et al. . Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood. 2019; 134:1337–1345 PubMed PMC

Voorhees PM, Kaufman JL, Laubach J, et al. . Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020; 136:936–945 PubMed PMC

Joseph NS, Kaufman JL, Dhodapkar MV, et al. . Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol. 2020; 38:1928–1937 PubMed PMC

Rosinol L, Hebraud B, Oriol A, et al. . Integrated analysis of bortezomib- lenalidomide-dexamethasone vs bortezomib-thalidomide-dexamethasone in transplant-eligible newly diagnosed myeloma. Clin Lymphoma Myeloma Leuk. 2019; 19supplE1–E2 PubMed

Moreau P, Attal M, Hulin C, et al. . Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019; 394:29–38 PubMed

Moreau P, Attal M, Hulin C, et al. . Phase 3 randomized study of daratumumab + bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible newly diagnosed multiple myeloma: CASSIOPEIA part 1 results. J Clin Oncol. 2019; 37suppl 158003

Gay F, Cerrato C, Petrucci M, et al. . Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: results from the FORTE trial. J Clin Oncol. 2019; 37suppl 158002

Blanes M, Lahuerta JJ, González JD, et al. . Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach. Biol Blood Marrow Transplant. 2013; 19:69–74 PubMed

Blanes M, Lorenzo JI, Ribas P, et al. . Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma. Ann Hematol. 2019; 98:2013–2015 PubMed

Roussel M, Hebraud B, Lauwers-Cances V, et al. . Bortezomib and high-dose melphalan vs. high-dose melphalan as conditioning regimen before autologous stem cell transplantation in de novo multiple myeloma patients: a phase 3 study of the Intergroupe Francophone Du Myelome (IFM 2014-02). Blood. 2017; 130suppl 1398 PubMed

Stadtmauer EA, Pasquini MC, Blackwell B, et al. . Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial. J Clin Oncol. 2019; 37:589–597 PubMed PMC

Hari P, Pasquini M, Stadtmauer E, et al. . Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM). J Clin Oncol. 2020; 38suppl 158506

Giralt S, Costa LJ, Maloney D, et al. . Tandem autologous-autologous versus autologous-allogeneic hematopoietic stem cell transplant for patients with multiple myeloma: long-term follow-up results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial. Biol Blood Marrow Transplant. 2020; 26:798–804 PubMed PMC

Attal M, Lauwers-Cances V, Marit G, et al. . Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012; 366:1782–1791 PubMed

McCarthy PL, Owzar K, Hofmeister CC, et al. . Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012; 366:1770–1781 PubMed PMC

McCarthy PL, Holstein SA, Petrucci MT, et al. . Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017; 35:3279–3289 PubMed PMC

Jackson GH, Davies FE, Pawlyn C, et al. . Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019; 20:57–73 PubMed PMC

Goldschmidt H, Lokhorst HM, Mai EK, et al. . Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. Leukemia. 2018; 32:383–390 PubMed

Dimopoulos MA, Gay F, Schjesvold F, et al. . Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2019; 393:253–264 PubMed

San Miguel JF, Schlag R, Khuageva NK, et al. . Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008; 359:906–917 PubMed

Benboubker L, Dimopoulos MA, Dispenzieri A, et al. . Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014; 371:906–917 PubMed

Durie BGM, Hoering A, Abidi MH, et al. . Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017; 389:519–527 PubMed PMC

Kumar S, Jacobus S, Cohen AD, et al. . Carfilzomib lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): results of ENDURANCE (E1A11) phase III trial. J Clin Oncol. 2020; 38(no. 18_suppl):Abstract LBA3

Mateos MV, Dimopoulos MA, Cavo M, et al. . Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018; 378:518–528 PubMed

Mateos MV, Cavo M, Blade J, et al. . Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020; 395:132–141 PubMed

Facon T, Kumar S, Plesner T, et al. . Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019; 380:2104–2115 PubMed PMC

Pönisch W, Mitrou PS, Merkle K, et al. . Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone–a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol. 2006; 132:205–212 PubMed

Palumbo A, Hajek R, Delforge M, et al. . Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012; 366:1759–1769 PubMed

Dimopoulos M, Špička I, Quach H, et al. . Ixazomib as postinduction maintenance for patients with newly diagnosed multiple lyeloma not undergoing autologous stem cell transplantation: the phase III TOURMALINE-MM4 trial J Clin Oncol. 2020; :4030–4041 PubMed PMC

Cook G, Ashcroft AJ, Cairns DA, et al. . The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. Lancet Haematol. 2016; 3:e340–e351 PubMed

Goldschmidt H, Baertsch MA, Schlenzka J, et al. . Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE. Leukemia. 2020July 21. [Epub ahead of print] PubMed

Giralt S, Garderet L, Durie B, et al. . American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group consensus conference on salvage hematopoietic cell transplantation in patients with relapsed multiple myeloma. Biol Blood Marrow Transplant. 2015; 21:2039–2051 PubMed PMC

Miller KC, Gertz MA, Buadi FK, et al. . The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplant. 2019; 54:2039–2050 PubMed PMC

Stewart AK, Rajkumar SV, Dimopoulos MA, et al. . Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015; 372:142–152 PubMed

Dimopoulos MA, Oriol A, Nahi H, et al. . Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016; 375:1319–1331 PubMed

Moreau P, Masszi T, Grzasko N, et al. . Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016; 374:1621–1634 PubMed

Lonial S, Dimopoulos M, Palumbo A, et al. . Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015; 373:621–631 PubMed

Siegel DS, Dimopoulos MA, Ludwig H, et al. . Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018; 36:728–734 PubMed

Dimopoulos M, Weisel K, Lonial S, et al. . Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: final overall survival results from the phase 3 ELOQUENT-2 trial. 17th International Myeloma Workshop, September 12–15, 2019, Boston, MA. Abstract OAB-021

Harousseau JL, Dimopoulos MA, Wang M, et al. . Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica. 2010; 95:1738–1744 PubMed PMC

Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. . Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017; 18:1327–1337 PubMed

Palumbo A, Chanan-Khan A, Weisel K, et al. . Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016; 375:754–766 PubMed

Richardson PG, Oriol A, Beksac M, et al. . Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019; 20:781–794 PubMed

Usmani S, Quach H, Mateos MV, et al. . Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma (RRMM): primary analysis results from the randomized, open-label, phase 3 study Candor (NCT03158688). Blood. 2019; 134:LBA-6

Moreau P, Dimopoulos MA, Mikhael J, et al. . Isatuximab plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (IKEMA): interim analysis of a phase 3, randomized, open-label study. Presented at: The European Hematology Association 25th Annual Congress, June 11–21, 2020. Virtual Congress: Abstract LBA2603

Gavriatopoulou M, Kastritis E, Ntanasis-Stathopoulos I, et al. . The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. Blood. 2018; 131:464–467 PubMed

Nooka AK, Joseph NS, Kaufman JL, et al. . Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: utility of re-treatment with daratumumab among refractory patients. Cancer. 2019; 125:2991–3000 PubMed

Kumar S, Harrison S, Cavo M, et al. . Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020;21:1630–1642. PubMed

Dimopoulos M, Delimpasi S, Simonova M, et al. . Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: initial results of the phase III BOSTON study. J Clin Oncol. 2020; 38no.15_supplAbstract 8501

Dimopoulos MA, Richardson PG, Moreau P, et al. . Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol. 2015; 12:42–54 PubMed

Gandhi UH, Cornell RF, Lakshman A, et al. . Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019; 33:2266–2275 PubMed PMC

Dimopoulos MA, Dytfeld D, Grosicki S, et al. . Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018; 379:1811–1822 PubMed

Attal M, Richardson PG, Rajkumar SV, et al. . Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019; 394:2096–2107 PubMed

Chari A, Suvannasankha A, Fay JW, et al. . Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017; 130:974–981 PubMed PMC

Chari A, Vogl DT, Gavriatopoulou M, et al. . Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019; 381:727–738 PubMed

Lonial S, Lee HC, Badros A, et al. . Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020; 21:207–221 PubMed

Richardson PG, Bringhen S, Voorhees P, et al. . Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. Lancet Haematol. 2020; 7:e395–e407 PubMed

Raje N, Berdeja J, Lin Y, et al. . Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019; 380:1726–1737 PubMed PMC

Fernandez de Larrea C, Kyle RA, Durie BG, et al. . Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013; 27:780–791 PubMed PMC

Gavriatopoulou M, Musto P, Caers J, et al. . European Myeloma Network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia. 2018; 32:1883–1898 PubMed

Musto P, Simeon V, Martorelli MC, et al. . Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia. 2014; 28:222–225 PubMed

Royer B, Minvielle S, Diouf M, et al. . Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase II study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2016; 34:2125–2132 PubMed

Van De Donk NWCJ, van der Holt B, Schjesvold FH, et al. . Treatment of primary plasma cell leukemia with carfilzomib and lenalidomide-based therapy: results of the first interim analysis of the phase 2 EMN12/HOVON129 study. Blood. 2019; 134suppl_1693

Dhakal B, Patel S, Girnius S, et al. . Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia. 2020; 34:3338–3347 PubMed PMC

Dimopoulos MA, Hamilos G. Solitary bone plasmacytoma and extramedullary plasmacytoma. Curr Treat Options Oncol. 2002; 3:255–259 PubMed

Paiva B, Chandia M, Vidriales MB, et al. . Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma. Blood. 2014; 124:1300–1303 PubMed

Dimopoulos MA, Hillengass J, Usmani S, et al. . Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol. 2015; 33:657–664 PubMed

Tsang RW, Campbell BA, Goda JS, et al. . Radiation therapy for solitary plasmacytoma and multiple myeloma: guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2018; 101:794–808 PubMed

Dykewicz CA; Centers for Disease Control and Prevention (U.S.); Infectious Diseases Society of America; American Society of Blood and Marrow Transplantation. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001; 33:139–144(Adapted from: Gross PA, Barrett TL, Dellinger EP, et al. Purpose of quality standards for infectious diseases. Clin Infect Dis. 1994;18:421.) PubMed

Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma

Limited efficacy of daratumumab in multiple myeloma with extramedullary disease